The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma
Open accessAbstract
UNLABELLED: CXCL5 (epithelial neutrophil-activating peptide-78) is a member of a proangiogenic subgroup of the CXC-type chemokine family of small, secreted proteins. Recently, evidence that CXCL5 is involved in carcinogenesis and cancer progression has emerged. To investigate the role of CXCL5 in tumor growth, invasion, and prognosis of hepatocellular carcinoma (HCC), we examined CXCL5 messenger RNA (mRNA) and protein levels in HCC cell lines with various metastatic potentials and in three independent cohorts of 919 HCC patients. We found that CXCL5 expression was increased in the highly metastatic HCC cell lines and in tumor tissues from patients with recurrent HCC compared to controls. CXCL5 activated the PI3K-Akt and ERK1/2 signaling pathways in HCC cells and promoted proliferation, migration, and invasion. Furthermore, we found that CXCL5 had a direct chemoattractant effect on neutrophils in vitro. In animal studies, the up-regulation of CXCL5 in HCC cells promoted tumor growth, lung metastasis, and intratumoral neutrophil infiltration. Conversely, down-regulation of CXCL5 in HCC cells reduced tumor growth, metastasis, and intratumoral neutrophil infiltration. Immunohistochemical analysis in HCC samples showed that overexpression of CXCL5 was well correlated with intratumoral neutrophil infiltration, shorter overall survival, and tumor recurrence. Multivariate analysis revealed that CXCL5 overexpression alone, or combined with the presence of intratumoral neutrophils, was an independent prognostic indicator for overall survival and cumulative recurrence. CONCLUSION: CXCL5 promotes HCC cell proliferation, invasion, and intratumoral neutrophil infiltration. CXCL5 overexpression, alone or combined with intratumoral neutrophil presence, is a novel prognostic predictor, and CXCL5 is a potential therapeutic target for HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
Neutrophil serine proteases: specific regulators of inflammation
Pham, C. T. N. (2006) · Nature Reviews Immunology · doi:10.1038/nri1841 · Cited by 1,022
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growth
Houghton, A. M., Rzymkiewicz, D. M., Ji, H., Gregory, A. D., Egea, E. E., Metz, H. E., Stolz, D. B., Land, S. R., Marconcini, L. A., Kliment, C. R., et al. (2010) · Nature Medicine · doi:10.1038/nm.2084 · Cited by 744
Chemokines and chemokine receptors: new insights into cancer-related inflammation
Lazennec, G., & Richmond, A. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.003 · Cited by 650
Mantovani, A. (2009) · Nature · doi:10.1038/457036b · Cited by 643
Heit, B., Tavener, S., Raharjo, E., & Kubes, P. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200202114 · Cited by 485
A decade?s studies on metastasis of hepatocellular carcinoma
Tang, Z.-Y., Ye, S.-L., Liu, Y.-K., Qin, L.-X., Sun, H.-C., Ye, Q.-H., Wang, L., Zhou, J., Qiu, S.-J., Li, Y., et al. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0511-1 · Cited by 418
Self-citationQueen, M. M., Ryan, R. E., Holzer, R. G., Keller-Peck, C. R., & Jorcyk, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1734 · Cited by 413
The chemokine system in cancer biology and therapy
Mantovani, A., Savino, B., Locati, M., Zammataro, L., Allavena, P., & Bonecchi, R. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.007 · Cited by 393
Immune cells as mediators of solid tumor metastasis
DeNardo, D. G., Johansson, M., & Coussens, L. M. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9100-0 · Cited by 372
Walz, A., Burgener, R., Car, B., Baggiolini, M., Kunkel, S. L., & Strieter, R. M. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.6.1355 · Cited by 353
Qiu, Y., Zhu, J., Bandi, V., Atmar, R. L., Hattotuwa, K., Guntupalli, K. K., & Jeffery, P. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-794oc · Cited by 351
Emerging mechanisms of neutrophil recruitment across endothelium
Williams, M. R., Azcutia, V., Newton, G., Alcaide, P., & Luscinskas, F. W. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.06.009 · Cited by 306
Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection
Li, Y.-W., Qiu, S.-J., Fan, J., Zhou, J., Gao, Q., Xiao, Y.-S., & Xu, Y.-F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.044 · Cited by 268
Self-citationKoch, A. E., Kunkel, S. L., Harlow, L. A., Mazarakis, D. D., Haines, G. K., Burdick, M. D., Pope, R. M., Walz, A., & Strieter, R. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117414 · Cited by 264
Arenberg, D. A., Keane, M. P., DiGiovine, B., Kunkel, S. L., Morris, S. B., Xue, Y. Y., Burdick, M. D., Glass, M. C., Iannettoni, M. D., & Strieter, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3145 · Cited by 259
Wislez, M., Rabbe, N., Marchal-Sommé, J., Milleron, B. J., Crestani, B., Mayaud, C. M., Antoine, M., Soler, P., & Cadranel, J. L. (2003) · PubMed · Cited by 243
McDonald, B., Spicer, J., Giannais, B., Fallavollita, L., Brodt, P., & Ferri, L. E. (2009) · International Journal of Cancer · doi:10.1002/ijc.24409 · Cited by 222
Yang, Y., Nagano, H., Ota, H., Morimoto, O., Nakamura, M., Wada, H., Noda, T., Damdinsuren, B., Marubashi, S., Miyamoto, A., et al. (2007) · Surgery · doi:10.1016/j.surg.2006.06.033 · Cited by 211
Overexpression of CXCL5 Is Associated With Poor Survival in Patients With Pancreatic Cancer
Li, A., King, J., Moro, A., Sugi, M. D., Dawson, D. W., Kaplan, J., Li, G., Lu, X., Strieter, R. M., Burdick, M., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2010.11.058 · Cited by 177
Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells
Takahashi, H., Numasaki, M., Lotze, M. T., & Sasaki, H. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.11.012 · Cited by 153
CXCL5 Promotes Prostate Cancer Progression
Begley, L., Kasina, S., Mehra, R., Adsule, S., Admon, A. J., Lonigro, R. J., Chinnaiyan, A. M., & Macoska, J. A. (2008) · Neoplasia · doi:10.1593/neo.07976 · Cited by 144
Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis
Wente, M. N., Keane, M. P., Burdick, M. D., Frieß, H., Büchler, M. W., Ceyhan, G. O., Reber, H. A., Strieter, R. M., & Hines, O. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.10.041 · Cited by 142
CXC‐chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer
Matsuo, Y., Raimondo, M., Woodward, T. A., Wallace, M. B., Gill, K. R., Tong, Z., Burdick, M. D., Yang, Z., Strieter, R. M., Hoffman, R. M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24383 · Cited by 140
Wong, Y. F., Cheung, T. H., Lo, K. W., Yim, S. F., Siu, N. S. S., Chan, S. C. S., Ho, T. W. F., Wong, K. W. Y., Yu, M. Y., Wang, Y., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209986 · Cited by 131
Down-regulation of CXCL5 Inhibits Squamous Carcinogenesis
Miyazaki, H., Patel, V., Wang, H., Edmunds, R. K., Gutkind, J. S., & Yeudall, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4398 · Cited by 110
CXCL5 overexpression is associated with late stage gastric cancer
Park, J. Y., Park, K. H., Bang, S., Kim, M., Lee, J.-E., Gang, J., Koh, S. S., & Song, S. Y. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0225-x · Cited by 105
Strell, C., Lang, K., Niggemann, B., Zaenker, K. S., & Entschladen, F. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.09.003 · Cited by 85
Enhanced ENA-78 and IL-8 Expression in Patients with Malignant Pancreatic Diseases
Frick, V. O., Rubie, C., Wagner, M., Graeber, S. M., Grimm, H., Kopp, B., Rau, B., & Schilling, M. K. (2008) · Pancreatology · doi:10.1159/000151776 · Cited by 51
Choi, M., Salanova, B., Rolle, S., Wellner, M., Schneider, W., Luft, F. C., & Kettritz, R. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070532 · Cited by 19
Cited by
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Roles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829
Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Huang, X.-W., Wang, Z., Chen, E.-B., Fan, J., Cao, Y., Dai, Z., & Zhou, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.040 · Cited by 852
Self-citationTumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy
Masucci, M. T., Minopoli, M., & Carriero, M. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01146 · Cited by 649
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donne, R., & Lujambio, A. (2023) · Hepatology · doi:10.1002/hep.32740 · Cited by 631
Metadata
- Authors
- Zhou, S.-L., Dai, Z., Zhou, Z.-J., Wang, X.-Y., Yang, G.-H., Wang, Z., Huang, X.-W., Fan, J., & Zhou, J.
- Venue
- Hepatology
- Published
- 2012-12
- Volume
- 56
- Issue
- 6
- Pages
- 2242-2254
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2071394435
- Cited by
- 356
- References
- 35
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.